Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2013-09-11 | recombinant human monoclonal IgM antibody targeting glucose-regulated protein 78 | Patrys (Australia) | plasma cell myeloma/multiple myeloma |
Granting of the orphan status in the US |
2013-09-11 | L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser | Araim Pharma Europe (UK) | sarcoidosis |
Granting of the orphan status in the EU |
2013-09-11 | mexiletine hydrochloride | Agenzia Industrie Difesa - Stabilimento Chimico Farmaceutico Militare (Italy) | myotonic disorders | Granting of the orphan status in the EU |
2013-09-11 | 3,5-diiodothyropropionic acid | CATS Consultants (Germany) | Allan-Herndon-Dudley syndrome The syndrome is an X-linked mental retardation syndrome with neuromuscular involvement characterized by hypotonia, muscular hypoplasia and intellectual deficit. This rare disorder of brain development occurs exclusively in males and disrupts development from before birth. |
|
2017-04-03 | antisense oligonucleotide targeting the F508 delta mutation of CFTR | ProQR Therapeutics (The Netherlands) | cystic fibrosis | Granting of a patent |
2015-03-16 | naproxcinod - nitronaproxen | NicOx (France) | Duchenne muscular dystrophy |
Granting of the orphan status in the US |
2013-09-11 | autologous CD34+ cells transduced with a lentiviral vector containing the humanWiskott-Aldrich syndrome gene | Généthon (France) | Wiskott-Aldrich syndrome | |
2013-07-10 | zoledronic acid | Axsome Therapeutics Limited (UK) | complex regional pain syndrome |
Granting of the orphan status in the EU |
2013-09-12 | GANYMED Pharmaceuticals (Germany) | |||
2013-09-17 | ofatumumab | GSK (UK) Genmab (Denmark) Novartis (Switzerland) | previously untreated chronic lymphocytic leukaemia (CLL) |
Granting of a Market Authorisation in the EU |
2013-09-18 | BioLineRx (Israel) | hepatitis C |
Granting of a patent | |
2013-09-19 | combination of two toxin-loaded anti-T-cell antibodies | Xenikos (The Netherland) | graft-versus-host disease (GVHD) | |
2013-09-22 | aripiprazole depot formulation | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | schizophrenia |
Acceptation for review of a sNDA |
2013-09-24 | elvitegravir | Gilead Sciences (USA - CA) | immunodeficiency virus-1 (HIV-1) infection in adults |
Submission of a Market Application in the US |
2014-12-19 | olaparib | AstraZeneca (UK) | relapsed, platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer with mutations in one of two genes called BRCA, and who have responded to platinum-based chemotherapy |
Granting of a Market Authorisation in the US |
2017-09-14 | elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg | Gilead Sciences (USA) |
|
Granting of a Market Authorisation in the EU |
2013-10-08 | GT Biologics (UK) | paediatric Crohn’s disease | ||
2013-10-08 | omalizumab | Novartis (Switzerland) Genentech (USA), Roche group (Switzerland) | chronic spontaneous urticaria (CSU) chronic idiopathic urticaria (CIU) |
|
2016-04-04 | BL-5010 | BioLineRx (Israel) Omega Pharma, now part of Perrigo (USA - MI) | non-surgical removal of skin lesions |
Granting of a Market Authorisation in the EU |
2017-02-16 | alectinib hydrochloride | Chugai (Japan) Roche (Switzerland) Genentech (USA - CA) | ALK fusion gene positive non-small cell lung cancer (NSCLC) | Granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+